GlassScriptPhysician profile
Daniel R Foitl
NPI 1861499147
$8,418.39
in general payments reported to CMS, 2019-2025
32 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,384 · 2021: $944 · 2022: $245 · 2023: $2,193 · 2024: $1,162 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $606 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $606.00 |
| Education | $180.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,603.76 | 2019-2025 | |
| Galderma Laboratories, L.P. | $828.27 | 2019-2025 | Nemluvio |
| Janssen Biotech, INC. | $772.22 | 2019-2024 | Tremfya |
| Leo Pharma INC. | $745.99 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $515.20 | 2019-2025 | |
| Pfizer INC. | $480.40 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $440.45 | 2020-2025 | Absorica Ld, Winlevi, Blu-U |
| Allergan, INC. | $363.22 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $335.65 | 2019-2025 | Cabtreo |
| Incyte Corporation | $246.22 | 2023-2025 | Opzelura |
| Lilly USA, LLC | $225.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $202.15 | 2023-2024 | Sotyktu |
| Ucb, INC. | $196.34 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $174.74 | 2019-2024 | |
| Almirall LLC | $153.95 | 2019-2025 | Seysara |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $142.52 | 2019-2023 | |
| Celgene Corporation | $140.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $126.48 | 2020-2022 | |
| Amgen INC. | $110.57 | 2023-2024 | Otezla |
| Sandoz INC. | $94.88 | 2019-2020 | |
| Dermira, INC. | $93.44 | 2020 | |
| Vyne Pharmaceuticals INC. | $82.32 | 2020 | |
| Strata Skin Sciences, INC. | $70.68 | 2023-2025 | Xtrac |
| Taro Pharmaceuticals USA, INC. | $46.05 | 2019 | |
| Dermavant Sciences, INC. | $45.53 | 2023 | Vtama |
| Mission Pharmacal Company | $32.62 | 2019-2021 | |
| Blueprint Medicines Corporation | $29.43 | 2023 | |
| Encore Dermatology INC. | $29.02 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $24.56 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.28 | 2019 | |
| Kyowa Kirin, INC. | $23.21 | 2023 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $19.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Foitl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.